2017
Feasibility, distribution, and efficacy of an inhaled oligonucleotide mimic of miR-29 for pulmonary fibrosis induced by bleomycin in rats
Montgomery R, Yu G, Ahangari F, Herazo-Maya J, Pestano L, Dalby C, Dickinson B, Nicholas C, Gallant-Behm C, Brower J, Kuehl P, McDonald J, Kaminski N. Feasibility, distribution, and efficacy of an inhaled oligonucleotide mimic of miR-29 for pulmonary fibrosis induced by bleomycin in rats. 2017, pa3480. DOI: 10.1183/1393003.congress-2017.pa3480.Peer-Reviewed Original ResearchPulmonary fibrosisMiR-29
2014
MicroRNA mimicry blocks pulmonary fibrosis
Montgomery RL, Yu G, Latimer PA, Stack C, Robinson K, Dalby CM, Kaminski N, van Rooij E. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Molecular Medicine 2014, 6: 1347-1356. PMID: 25239947, PMCID: PMC4287936, DOI: 10.15252/emmm.201303604.Peer-Reviewed Original Research
2011
MicroRNAs in idiopathic pulmonary fibrosis
Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Translational Research 2011, 157: 191-199. PMID: 21420029, DOI: 10.1016/j.trsl.2011.01.012.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisIPF lungsPulmonary fibrosisLung fibrosisMiR-155Vascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayLethal fibrotic lung diseaseFibrotic lung diseaseMiR-29Upregulated miR-155Growth factor-β1Epithelial-mesenchymal transitionGrowth factor pathwaysLung epithelial cellsLung diseaseProfibrotic effectsBleomycin modelRole of microRNAsTherapeutic targetFactor-β1FibrosisMesenchymal transitionFactor pathwayLet-7 family members